Valproic acid (VPA) prevents small cell lung carcinoma (SCLC) tumour growth in combination with cyclophosphamide, vindesine and doxorubicin. Valproic acid.

Slides:

Advertisements

Similar presentations

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Advertisements

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.

Compliance of the respiratory system (Crs) at baseline and 0 h, 1 h and 2 h following lung volume recruitment. a) Absolute Crs in the respiratory muscle.

Flowchart for calculating the relative risk (RR) for cancer X and lung cancer (LC). Flowchart for calculating the relative risk (RR) for cancer X and lung.

Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.

Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)

Fig. 8. In vivo suppression of MM by CMLD

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.

Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative.

Effect of caspase-1 deficiency on lung inflammatory parameters and inflammatory cell subsets in a mouse model of asthma exacerbation. Effect of caspase-1.

Bland–Altman plot of slopes of measurement 1 versus 2

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

Function of recoded cystic fibrosis transmembrane conductance regulator (CFTR) channels. a) Representative recordings obtained from HEK293 cells expressing.

Lung interleukin (IL)-33 protein expression in vivo depends on caspase-1. Lung interleukin (IL)-33 protein expression in vivo depends on caspase-1. Mice.

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Caspase-1 deficient mice have a lower expression of lung T-helper type 2 (Th2)-upstream cytokines at exacerbation. Caspase-1 deficient mice have a lower.

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Volume 62, Issue 2, Pages (February 2015)

Nicholas D. James, Jim W. Growcott European Urology Supplements

Swimmer plots showing post-nivolumab progression-free survival for the three main drugs studied according to the line of treatment in which they were received.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Induced pleurodesis depending on the two techniques

In vivo efficacy of Olaparib in PTEN deficient xenografts.

Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.

Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration.

Protein expression profiling of small cell lung carcinoma treated with valproic acid (VPA) and VAC (mafosfamide, doxorubicin and vindesine). Protein expression.

Measurement of a) IL-8, b) IL-6 and c) GM-CSF release by BEAS-2B cells stimulated with deoxycholic acid for 48 h. Measurement of a) IL-8, b) IL-6 and c)

Valproic acid (VPA) synergises with VAC (mafosfamide, doxorubicin and vindesine) to induce apoptosis in small cell lung carcinoma (SCLC) cell lines. Valproic.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Effect of MI-773 and/or cisplatin in a preclinical model of ACC

Forest plot of adjusted odds ratios (with 95% confidence intervals) from multivariable multinomial logistic regression analysis (table 4), by number of.

Effect of MI-773 dosing on long-term efficacy.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) for EGFR mutant lung adenocarcinoma.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Physician perspectives on the most useful methods for monitoring α1-antitrypsin deficiency in the clinical trial setting versus clinical practice. Physician.

Differences in a) functional residual capacity (FRC) and b) lung clearance index (LCI) when using all trials in comparison with only the first two trials.

Physician perspectives on self-administration of i. v. α1-antitrypsin

Post-operative a) neutrophil counts, but not b) lymphocyte or c) platelet counts, were higher in current smokers than ex-smokers. #: time-points were statistically.

Change in the regular use of inhaled corticosteroids (as a single inhaler or in combination; any use in the last 12 months) in participants with persistent.

TFAP2A knockdown inhibits tumor growth in vivo.

The selective depletion of DTR-expressing FAP+/CD45+ and FAP+/CD45− tumoral cells from bone marrow chimeric mice by the administration of DTX. A, sketch.

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

Composition of the most common clusters at the a) onset of the first acute respiratory tract infection (swab A) and b) 3 weeks later (swab B) illustrated.

Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo). Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo).

Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.

B. fragilis utilizes TLR2 signaling for its protective role against the development of colitis-associated cancer in mice. B. fragilis utilizes TLR2 signaling.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Comparison of cancer-specific survival in patients with nonsmall cell lung cancer detected incidentally by computed tomography (CT) (n=41) or chest radiography.

GCS-100 selectively kills KRAS-addicted lung tumors.

Colonization with B. fragilis protects mice against development of colon cancer. Colonization with B. fragilis protects mice against development of colon.

Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

Valproic acid (VPA) prevents small cell lung carcinoma (SCLC) tumour growth in combination with cyclophosphamide, vindesine and doxorubicin. Valproic acid (VPA) prevents small cell lung carcinoma (SCLC) tumour growth in combination with cyclophosphamide, vindesine and doxorubicin. Two human SCLC cell lines (H69 (a) and H146 (b)) were injected subcutaneously into severe combined immunodeficiency mice in 50% matrigel. Groups of at least six mice were tested in each experimental condition. When tumours reached a volume of 300–400 mm³, mice were administered with daily intraperitoneal injections of VPA (400 mg·kg−1·day−1) or PBS as a control. 3 days after the first VPA administration, intraperitoneal injections of cyclophosphamide (40 mg·kg−1), vindesin (0.5 mg·kg−1) and doxorubicin (3 mg·kg−1) were performed (at days 14 and 17, and days 8, 13, 25 and 34 for H69 and H146, respectively (arrows)). The tumour volume (in cubic millimetres) is presented as means±sd and was calculated at regular intervals of time. There is a statistical significant difference according to the Student's t-test: **: p<0.01 for VAC+VPA versus VAC only treatments. Roland Hubaux et al. ERJ Open Res 2015;1:00028-2015 ©2015 by European Respiratory Society